NASDAQ: GTBP · Life Sciences · 4 alerts · CIK 109657
Share price
$3.54Close, Nov 16
Market cap
$7.56M
Shares outstanding
2.14MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All GT Biopharma, Inc. filings on SEC EDGAR ↗
GT Biopharma reported a net loss of $10.88 million for the nine months ended September 30, 2026, compared to a loss of $22.65 million in the prior year period. The company transitioned to a fully remote model as of July 2024 and maintained a cash balance of $9.92 million as of the reporting date.
GT Biopharma shareholders approved a significant increase in authorized common shares from 25 million to 250 million and authorized the issuance of more than 19.99% of outstanding stock. These approvals facilitate the conversion of Series M Preferred Stock and the exercise of warrants related to a Securities Purchase Agreement dated September 14, 2026. The vote ensures compliance with Nasdaq Rule 5635 regarding the potential dilution from these previously announced financing transactions.
GT Biopharma amended its securities purchase agreement to increase a private placement of Series M 10% Convertible Preferred Stock and warrants, raising the aggregate purchase price to $7.75 million. The deal includes 'Greenshoe Rights' allowing purchasers to potentially acquire additional preferred stock with an aggregate stated value of up to approximately $34.7 million. The company has committed to filing a registration statement for the resale of the underlying common stock within 30 days of closing.
GT Biopharma entered into a securities purchase agreement for a private placement of up to 8,277.778 shares of Series M 10% Convertible Preferred Stock and associated warrants for an initial purchase price of $7.45 million. The agreement includes 'Greenshoe Rights' allowing purchasers to acquire additional preferred stock with a stated value of up to $33.33 million for an additional $30 million. The preferred stock is convertible into common stock at an initial conversion price of $6.10 per share.